Kymera Therapeutics. has filed a patent for compounds, compositions, and methods of using them. The claim numbers 1-26 have been canceled. GlobalData’s report on Kymera Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kymera Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Kymera Therapeutics's grant share as of January 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20240024318A1) describes a method for degrading specific proteins in a patient or biological sample by administering a compound of formula I-a-3. This method aims to treat disorders, diseases, or conditions mediated by SMARCA2, SMARCA4, or PB1 proteins by targeting these proteins with the compound. The treatment method can also involve the administration of additional therapeutic agents to enhance the efficacy of the compound. The disorders that can be targeted by this method include various types of cancers, neurodegenerative diseases, autoimmune diseases, inflammatory disorders, and metabolic disorders, among others.
The compound used in the method is formulated with a pharmaceutical composition that includes a pharmaceutically acceptable carrier, adjuvant, or vehicle. The chemical structure of the compound includes specific elements such as Ring Y, Rx, Ry, X1, X2, X3, R1, R2, Ring A, Ring B, LBM, L, and Cy, which play a crucial role in its mechanism of action. These structural components are carefully designed to interact with the target proteins and facilitate their degradation. By utilizing this method, healthcare professionals can potentially address a wide range of disorders and conditions associated with the malfunctioning of SMARCA2, SMARCA4, or PB1 proteins, offering new possibilities for therapeutic interventions in various medical fields.
To know more about GlobalData’s detailed insights on Kymera Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
